Source: Reuters The Securities and Exchange Commission is concerned about the way Canadian drugmaker Valeant Pharmaceuticals International Inc (VRX.TO) has been disclosing its "non-GAAP" financial measures, regulatory filings showed on Tuesday. The SEC has questioned Valeant's practice of stripping away acquisition-related expenses from its "non-GAAP" or adjusted metrics, given that…...